PravinUDugelMD

Ophthalmology • Phoenix, AZ

Retinal Disease

Physician

Join to view full profile

Are you Dr. Dugel?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 61 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1101 E Missouri Ave
Phoenix, AZ 85014
Phone+1 602-222-2221

Fax+1 602-266-2044

Summary

Dr. Pravin Dugel, MD is a board certified ophthalmologist in Phoenix, Arizona. He is currently licensed to practice medicine in Arizona and California. He is affiliated with St. Joseph's Hospital and Medical Center, HonorHealth Scottsdale Osborn Medical Center, and HonorHealth Deer Valley Medical Center.

Education & Training

University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Ophthalmology, 1988 - 1994
David Geffen School of Medicine at UCLAClass of 1988

Certifications & Licensure

AZ State Medical License 1994 - 2026
CA State Medical License 1990 - 2025
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy Start of enrollment: 2006 Sep 01
Completed
Phase 1
A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration Start of enrollment: 2007 Apr 01
Unknown status
Phase 3
Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema Start of enrollment: 2005 Jun 01
Completed
Phase 1
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) Start of enrollment: 2012 Feb 01
Terminated
Phase 2
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus Start of enrollment: 2012 Nov 01
Completed
Phase 2
Topcon Endpoint Management Start of enrollment: 2012 Aug 01
Completed
Not Applicable
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) Start of enrollment: 2013 May 01
Completed
Phase 4
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD Start of enrollment: 2015 Jul 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema.
David S Boyer, Nathan C Steinle, Joel A Pearlman, Cameron M Stone, Courtney Crawford
Translational Vision Science & Technology. 2024-12-02
19 citations
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
Timothy L Jackson, Jason Slakter, Marc Buyse, Kun Wang, Pravin U Dugel
Ophthalmology. 2023-06-01
12 citations
Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study.
Einar Stefansson, Thorstein Loftsson, Michael Larsen, András Papp, Kai Kaarniranta
Acta Ophthalmologica. 2023-02-01

Authored Content

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Join now to see all

Press Mentions

IVERIC Bio, Inc. (NASDAQ:ISEE) Q4 2022 Earnings Call TranscriptMarch 3rd, 2023
IVERIC Bio, Inc. (ISEE) Q1 2022 Earnings Call TranscriptMay 4th, 2022
Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of ScheduleJuly 26th, 2021
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow